InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.016 -0.012 (-42.86%)+
Announcement
Release
29 Oct 2025 9:49AM
Price at Release
$0.028
Full Release
download
Summary
Atomo Diagnostics Limited has released its Appendix 4C and quarterly activities report for Q1 FY26, reflecting a period of substantial progress. Significant achievements include the submission of the FebriDx test for a CLIA waiver with the US FDA, supported by excellent performance in US clinical trials. The company received purchase orders worth approximately $1 million from Lumos for Pascal cassettes, with expectations of increased demand. Atomo also reported strong growth in its HIV Self-Test business, including launching on the Chemist Warehouse ecommerce site and securing international orders. The company is making strides with its Active Syphilis Test, demonstrating market-leading specificity. Financially, Atomo reported total revenue of $680k and ended the quarter with $3.39 million in cash, aided by a successful capital raise and a CRC-P grant.
Key Points
  • Atomo submitted FebriDx for CLIA waiver approval.
  • Pascal cassette orders from Lumos amount to ~$1 million.
  • HIV Self-Test launched on Chemist Warehouse ecommerce site.
  • Active Syphilis Test shows promising clinical results.
  • Total revenue for Q1 FY26 was $680k.
  • Cash on hand at quarter-end was $3.39 million.
  • Received a CRC-P grant and closed a capital raising round.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.